Home > Oncology > ESMO 2021 > Breast Cancer > Asian women also benefit from palbociclib plus letrozole

Asian women also benefit from palbociclib plus letrozole

Presented By
Prof. Binghe Xu, Peking Union Medical College, Beijing, China
Conference
ESMO 2021
Trial
Phase 3, PALOMA-4
Results from the PALOMA-4 trial confirmed that palbociclib plus letrozole significantly prolonged progression-free survival (PFS) as compared with placebo plus letrozole in an Asian cohort in the first-line setting for ER-positive, HER2-negative advanced breast cancer. Prof. Binghe Xu (Peking Union Medical College, Beijing, China) presented results of PALOMA-4 (NCT02297438), currently the largest randomised phase 3 study of a CDK4/6 inhibitor in Asian women with ER-positive, HER2-negative advanced breast cancer in the first-line setting [1]. The multicentre, randomised, double-blind phase 3 study PALOMA-4 was designed to compare the clinical benefit following treatment with letrozole in combination with palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER-positive, HER2-negative advanced breast cancer who have not received...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on